,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': 'Created a community application following several Extraordinary Circumstance applications for these products.', 'fs': 'Created a community application following several Extraordinary Circumstance applications for these products.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2010', 'fs': 'May 2010', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000070wiBUAQ'}, 'Id': 'a0P2P0000070wiBUAQ', 'Event_Date__c': '2010-05-12', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Summary__c': 'Created a community application following several Extraordinary Circumstance applications for these products.', 'Formatted_Date__c': 'May 2010', 'Status_History__c': 'a132P000000ApaaQAC'}, 'change': None}]",May 2010,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Medium to High', 'fs': 'Medium to High', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-ophthalmology-subcommittee-minutes-2010-05.pdf"" target=""_blank"">Ophthalmology Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-ophthalmology-subcommittee-minutes-2010-05.pdf"" target=""_blank"">Ophthalmology Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'May 2010', 'fs': 'May 2010', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Ophthalmology Subcommittee at meeting Friday 14 May 2010.', 'fs': 'Clinical advice received from Ophthalmology Subcommittee at meeting Friday 14 May 2010.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000070wiCUAQ'}, 'Id': 'a0P2P0000070wiCUAQ', 'Event_Date__c': '2010-05-14', 'Event_Description__c': 'Clinical advice received from Ophthalmology Subcommittee at meeting Friday 14 May 2010.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-ophthalmology-subcommittee-minutes-2010-05.pdf"" target=""_blank"">Ophthalmology Subcommittee minutes</a>', 'Outcome__c': 'Medium to High', 'Formatted_Date__c': 'May 2010', 'Status_History__c': 'a132P000000ApacQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Medium to High', 'fs': 'Medium to High', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2010-08.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2010-08.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Aug 2010', 'fs': 'Aug 2010', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 5 August 2010.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 5 August 2010.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000070wiDUAQ'}, 'Id': 'a0P2P0000070wiDUAQ', 'Event_Date__c': '2010-08-05', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 5 August 2010.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2010-08.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Medium to High', 'Formatted_Date__c': 'Aug 2010', 'Status_History__c': 'a132P000000ApdmQAC'}, 'change': None}, {'Summary': {'s': 'The Subcommittee noted that ciclosporin 0.2% eye ointment and ciclosporin eye drops (0.05%, single dose) are not widely used in DHB hospitals, but recommended that they be included in a national PML.    The Subcommittee recommended that the prescribing of ciclosporin eye ointment and eye drops be subject to recommendation by an ophthalmologist.', 'fs': 'The Subcommittee noted that ciclosporin 0.2% eye ointment and ciclosporin eye drops (0.05%, single dose) are not widely used in DHB hospitals, but recommended that they be included in a national PML.    The Subcommittee recommended that the prescribing of ciclosporin eye ointment and eye drops be subject to recommendation by an ophthalmologist.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Recommended for funding with no priority', 'fs': 'Recommended for funding with no priority', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-sensory-organs-group-minutes-2012-09.pdf"" target=""_blank"">Hospital Pharmaceuticals Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-sensory-organs-group-minutes-2012-09.pdf"" target=""_blank"">Hospital Pharmaceuticals Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Jul 2011', 'fs': 'Jul 2011', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Hospital Pharmaceuticals Subcommittee at meeting Tuesday 5 July 2011.', 'fs': 'Clinical advice received from Hospital Pharmaceuticals Subcommittee at meeting Tuesday 5 July 2011.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000070wiEUAQ'}, 'Id': 'a0P2P0000070wiEUAQ', 'Event_Date__c': '2011-07-05', 'Event_Description__c': 'Clinical advice received from Hospital Pharmaceuticals Subcommittee at meeting Tuesday 5 July 2011.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-sensory-organs-group-minutes-2012-09.pdf"" target=""_blank"">Hospital Pharmaceuticals Subcommittee minutes</a>', 'Outcome__c': 'Recommended for funding with no priority', 'Summary__c': 'The Subcommittee noted that ciclosporin 0.2% eye ointment and ciclosporin eye drops (0.05%, single dose) are not widely used in DHB hospitals, but recommended that they be included in a national PML.    The Subcommittee recommended that the prescribing of ciclosporin eye ointment and eye drops be subject to recommendation by an ophthalmologist.', 'Formatted_Date__c': 'Jul 2011', 'Status_History__c': 'a132P000000AprBQAS'}, 'change': None}, {'Summary': {'s': 'The Subcommittee noted that it had previously recommended that ciclosporin eye drops and ointment be included in a national PML, and noted that the Ophthalmology Subcommittee has recommended that this be a community-led funding decision.', 'fs': 'The Subcommittee noted that it had previously recommended that ciclosporin eye drops and ointment be included in a national PML, and noted that the Ophthalmology Subcommittee has recommended that this be a community-led funding decision.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'No Formal Recommendation', 'fs': 'No Formal Recommendation', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-sensory-organs-group-minutes-2012-09.pdf "" target=""_blank"">Hospital Pharmaceuticals Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-sensory-organs-group-minutes-2012-09.pdf "" target=""_blank"">Hospital Pharmaceuticals Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Mar 2012', 'fs': 'Mar 2012', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Hospital Pharmaceuticals Subcommittee at meeting Tuesday 6 March 2012.', 'fs': 'Clinical advice received from Hospital Pharmaceuticals Subcommittee at meeting Tuesday 6 March 2012.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000070wiFUAQ'}, 'Id': 'a0P2P0000070wiFUAQ', 'Event_Date__c': '2012-03-06', 'Event_Description__c': 'Clinical advice received from Hospital Pharmaceuticals Subcommittee at meeting Tuesday 6 March 2012.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-sensory-organs-group-minutes-2012-09.pdf "" target=""_blank"">Hospital Pharmaceuticals Subcommittee minutes</a>', 'Outcome__c': 'No Formal Recommendation', 'Summary__c': 'The Subcommittee noted that it had previously recommended that ciclosporin eye drops and ointment be included in a national PML, and noted that the Ophthalmology Subcommittee has recommended that this be a community-led funding decision.', 'Formatted_Date__c': 'Mar 2012', 'Status_History__c': 'a132P000000ApzJQAS'}, 'change': None}, {'Summary': {'s': 'The Subcommittee considered that cyclosporin eye ointment 0.2% or eye drops 0.05% single dose preparations should be a community-led listing and recommended PHARMAC staff seek a listing when a product became registered.', 'fs': 'The Subcommittee considered that cyclosporin eye ointment 0.2% or eye drops 0.05% single dose preparations should be a community-led listing and recommended PHARMAC staff seek a listing when a product became registered.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'No Formal Recommendation', 'fs': 'No Formal Recommendation', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-sensory-organs-group-minutes-2012-09.pdf "" target=""_blank"">Ophthalmology Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-sensory-organs-group-minutes-2012-09.pdf "" target=""_blank"">Ophthalmology Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Mar 2012', 'fs': 'Mar 2012', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Ophthalmology Subcommittee at meeting Friday 9 March 2012.', 'fs': 'Clinical advice received from Ophthalmology Subcommittee at meeting Friday 9 March 2012.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000070wiGUAQ'}, 'Id': 'a0P2P0000070wiGUAQ', 'Event_Date__c': '2012-03-09', 'Event_Description__c': 'Clinical advice received from Ophthalmology Subcommittee at meeting Friday 9 March 2012.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-sensory-organs-group-minutes-2012-09.pdf "" target=""_blank"">Ophthalmology Subcommittee minutes</a>', 'Outcome__c': 'No Formal Recommendation', 'Summary__c': 'The Subcommittee considered that cyclosporin eye ointment 0.2% or eye drops 0.05% single dose preparations should be a community-led listing and recommended PHARMAC staff seek a listing when a product became registered.', 'Formatted_Date__c': 'Mar 2012', 'Status_History__c': 'a132P000000ApzRQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'No Formal Recommendation', 'fs': 'No Formal Recommendation', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2012-05.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2012-05.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'May 2012', 'fs': 'May 2012', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 10 May 2012.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 10 May 2012.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000070wiHUAQ'}, 'Id': 'a0P2P0000070wiHUAQ', 'Event_Date__c': '2012-05-10', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 10 May 2012.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2012-05.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'No Formal Recommendation', 'Formatted_Date__c': 'May 2012', 'Status_History__c': 'a132P000000Aq2LQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jul 2013', 'fs': 'Jul 2013', 'change': None}, 'Event_Description': {'s': 'There is no Medsafe-registered product. PHARMAC may reconsider this proposal once a product is registered or a supplier approaches PHARMAC.', 'fs': 'There is no Medsafe-registered product. PHARMAC may reconsider this proposal once a product is registered or a supplier approaches PHARMAC.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000070wiIUAQ'}, 'Id': 'a0P2P0000070wiIUAQ', 'Event_Date__c': '2013-07-01', 'Event_Description__c': 'There is no Medsafe-registered product. PHARMAC may reconsider this proposal once a product is registered or a supplier approaches PHARMAC.', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Jul 2013', 'Status_History__c': 'a132P000000AqR9QAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2016', 'fs': 'Feb 2016', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000070wiJUAQ'}, 'Id': 'a0P2P0000070wiJUAQ', 'Event_Date__c': '2016-02-01', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Feb 2016', 'Status_History__c': 'a132P000000Ar3zQAC'}, 'change': None}, {'Summary': {'s': '<p>Recommended that ciclosporin 0.05% eye preparation be funded for the treatment of vernal keratoconjunctivitis (VKC) atopic keratoconjunctivitis (AKC) and the treatment of dry eye disease, secondary to secretive dysfunction, responsive to steroid treatment. Full recommended Special Authority given in minutes.</p>', 'fs': '<p>Recommended that ciclosporin 0.05% eye preparation be funded for the treatment of vernal keratoconjunctivitis (VKC) atopic keratoconjunctivitis (AKC) and the treatment of dry eye disease, secondary to secretive dysfunction, responsive to steroid treatment. Full recommended Special Authority given in minutes.</p>', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Medium', 'fs': 'Medium', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-ophthalmology-subcommittee-minutes-2016-02.pdf"" target=""_blank"">Ophthalmology Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-ophthalmology-subcommittee-minutes-2016-02.pdf"" target=""_blank"">Ophthalmology Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Feb 2016', 'fs': 'Feb 2016', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Ophthalmology Subcommittee at meeting Wednesday 24 February 2016.', 'fs': 'Clinical advice received from Ophthalmology Subcommittee at meeting Wednesday 24 February 2016.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000070wiKUAQ'}, 'Id': 'a0P2P0000070wiKUAQ', 'Event_Date__c': '2016-02-24', 'Event_Description__c': 'Clinical advice received from Ophthalmology Subcommittee at meeting Wednesday 24 February 2016.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-ophthalmology-subcommittee-minutes-2016-02.pdf"" target=""_blank"">Ophthalmology Subcommittee minutes</a>', 'Outcome__c': 'Medium', 'Summary__c': '<p>Recommended that ciclosporin 0.05% eye preparation be funded for the treatment of vernal keratoconjunctivitis (VKC) atopic keratoconjunctivitis (AKC) and the treatment of dry eye disease, secondary to secretive dysfunction, responsive to steroid treatment. Full recommended Special Authority given in minutes.</p>', 'Formatted_Date__c': 'Feb 2016', 'Status_History__c': 'a132P000000Ar5uQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Deferred', 'fs': 'Deferred', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2016-05.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2016-05.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'May 2016', 'fs': 'May 2016', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 5 May 2016.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 5 May 2016.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000070wiMUAQ'}, 'Id': 'a0P2P0000070wiMUAQ', 'Event_Date__c': '2016-05-05', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 5 May 2016.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2016-05.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Deferred', 'Formatted_Date__c': 'May 2016', 'Status_History__c': 'a132P000000Ar8IQAS'}, 'change': None}, {'Summary': {'s': '<p>The Committee recommended ciclosporin\xa0preparation at a strength higher than 0.05% be funded on the Pharmaceutical Schedule for the treatment of severe vernal or atopic keratoconjunctivitis sicca with a high priority with an amended Special Authority. The Committee also recommended ciclosporin 0.05% preparation be funded for the treatment of severe keratoconjunctivitis sicca with a low priority with an amended Special Authority.</p>', 'fs': '<p>The Committee recommended ciclosporin\xa0preparation at a strength higher than 0.05% be funded on the Pharmaceutical Schedule for the treatment of severe vernal or atopic keratoconjunctivitis sicca with a high priority with an amended Special Authority. The Committee also recommended ciclosporin 0.05% preparation be funded for the treatment of severe keratoconjunctivitis sicca with a low priority with an amended Special Authority.</p>', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2016-08.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2016-08.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Aug 2016', 'fs': 'Aug 2016', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 11 August 2016.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 11 August 2016.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000070wiNUAQ'}, 'Id': 'a0P2P0000070wiNUAQ', 'Event_Date__c': '2016-08-11', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 11 August 2016.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2016-08.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'High', 'Summary__c': '<p>The Committee recommended ciclosporin\xa0preparation at a strength higher than 0.05% be funded on the Pharmaceutical Schedule for the treatment of severe vernal or atopic keratoconjunctivitis sicca with a high priority with an amended Special Authority. The Committee also recommended ciclosporin 0.05% preparation be funded for the treatment of severe keratoconjunctivitis sicca with a low priority with an amended Special Authority.</p>', 'Formatted_Date__c': 'Aug 2016', 'Status_History__c': 'a132P000000ArBHQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'No Formal Recommendation', 'fs': 'No Formal Recommendation', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-ophthalmology-subcommittee-minutes-2017-09.pdf"" target=""_blank"">Ophthalmology Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-ophthalmology-subcommittee-minutes-2017-09.pdf"" target=""_blank"">Ophthalmology Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Sep 2017', 'fs': 'Sep 2017', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Ophthalmology Subcommittee at meeting Wednesday 20 September 2017.', 'fs': 'Clinical advice received from Ophthalmology Subcommittee at meeting Wednesday 20 September 2017.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000070wiQUAQ'}, 'Id': 'a0P2P0000070wiQUAQ', 'Event_Date__c': '2017-09-20', 'Event_Description__c': 'Clinical advice received from Ophthalmology Subcommittee at meeting Wednesday 20 September 2017.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-ophthalmology-subcommittee-minutes-2017-09.pdf"" target=""_blank"">Ophthalmology Subcommittee minutes</a>', 'Outcome__c': 'No Formal Recommendation', 'Formatted_Date__c': 'Sep 2017', 'Status_History__c': 'a132P000000ArL8QAK'}, 'change': None}]",May 2010,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2016', 'fs': 'Feb 2016', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000070wiLUAQ'}, 'Id': 'a0P2P0000070wiLUAQ', 'Event_Date__c': '2016-02-24', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Feb 2016', 'Status_History__c': 'a132P000000Ar5wQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2016', 'fs': 'Aug 2016', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000070wiOUAQ'}, 'Id': 'a0P2P0000070wiOUAQ', 'Event_Date__c': '2016-08-11', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Aug 2016', 'Status_History__c': 'a132P000000ArBJQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2022', 'fs': 'Sep 2022', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000070wiRUAQ'}, 'Id': 'a0P2P0000070wiRUAQ', 'Event_Date__c': '2022-09-06', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Sep 2022', 'Status_History__c': 'a132P000000E2LDQA0'}, 'change': None}]",Feb 2016,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmacâ€™s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2017', 'fs': 'Jun 2017', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000070wiPUAQ'}, 'Id': 'a0P2P0000070wiPUAQ', 'Event_Date__c': '2017-06-08', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Jun 2017', 'Status_History__c': 'a132P000000ArInQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jan 2023', 'fs': 'Jan 2023', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P0000070wiSUAQ'}, 'Id': 'a0P2P0000070wiSUAQ', 'Event_Date__c': '2023-01-26', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Jan 2023', 'Status_History__c': 'a132P000000EDJfQAO'}, 'change': None}]",Jun 2017,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,,,False,False
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,,,False,False
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,,,False,False
